Avoid common mistakes on your manuscript.
Correction to: Ophthalmol Ther (2018) 7:157–165 https://doi.org/10.1007/s40123-018-0130-1
In the original publication, units were incorrectly published in the results section as micrograms (µg/mL). The correct units are nanograms (ng/mL). The updated results section and an updated version of Fig. 1 are below.
Aqueous Humor Analyte Pharmacokinetics
The NSAID aqueous humor Cmax of BromSite® BID was 1.7-, 2.2- and 3.7-fold higher than that of BromSite® QD, Prolensa®, and Ilevro®, respectively. The Cmax for Ilevro® occurred at 1 h and for the other three groups at 2 h (Fig. 1a). The Bromsite® BID group had the highest Cmax at 131 ng/mL, followed by Bromsite® QD (77 ng/mL) and Prolensa® (59 ng/mL), while Ilevro® group was much lower at 35 ng/mL. The Cmax in the Bromsite® BID group was statistically significantly higher (p < 0.05) than that of Prolensa® and Ilevro®.
Concentration–time profile at each matrix. The standard error bars (upper only) are presented. a Aqueous humor concentration–time profile. b Iris ciliary body concentration–time profile. c Sclera concentration–time profile. d Choroid concentration–time profile. e Retina concentration–time profile
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Sheppard, J.D., Cockrum, P.C., Justice, A. et al. Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits. Ophthalmol Ther 8, 347–348 (2019). https://doi.org/10.1007/s40123-019-0172-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40123-019-0172-z